C1orf116 is a novel EMT biomarker for prostate cancer, and our study showed 17-fold and 24-fold downregulation of this gene in taxane-resistant prostate cancer subtypes DUTXR and PC-3TXR, respectively. This evidence concerns the gene C1orf116 and prostate carcinoma.